Evidence map›Paper›PMID 15860191›Full record

ReviewRevista clinica espanola2005

[Gene therapy: current situation and expectations].

R Alemany Bonastre, J Barquinero Máñez, S Ramón y Cajal Agueras

Abstract readEnglish AbstractReview
In one paragraph

Review in Revista clinica espanola, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

R Alemany BonastreLaboratori de Recerca Translacional, Institut Català d'Oncologia, Barcelona.
J Barquinero Máñez
S Ramón y Cajal Agueras

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this review the current situation of gene therapy is described in hematological diseases, immunological conditions, and cancer. In all of them, the principal objective of various approaches with gene therapy is transduction of therapeutic genes in most of target cells. In chronic or immunological diseases, a stable expression of therapeutic genes is also required; in tumor cells, the efficiency or percentage of transduced cells make conditional on the treatment success. Consequently, vectors are one of the basic elements to optimize gene therapy approaches and protocols in view of the facts that we know that with liposomes less than 10% of cells are transduced, that retrovirus only infect cells in replication, and that adenovirus give rise to an important inflammatory response and a transitory transduction of the therapeutic gene. In addition recent approaches in cancer gene therapy with selective replication virus, suicidal genes, etc., are discussed.

Indexed as

Genetic TherapyGenetic VectorsAnimalsHematologic DiseasesHumansImmune System DiseasesNeoplasms

Identifiers

PMID15860191
PMCPMC7130155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.